

Ken Kato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3225424/publications.pdf>

Version: 2024-02-01

135
papers

11,408
citations

70961

41
h-index

33814

99
g-index

137
all docs

137
docs citations

137
times ranked

8224
citing authors

#	ARTICLE	IF	CITATIONS
1	Transnasal photoimmunotherapy with cetuximab sarotalocan sodium: Outcomes on the local recurrence of nasopharyngeal squamous cell carcinoma. <i>Auris Nasus Larynx</i> , 2023, 50, 641-645.	0.5	7
2	The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 55-65.	1.0	11
3	Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181. <i>Esophagus</i> , 2022, 19, 137-145.	1.0	8
4	Prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502. <i>Cancer Science</i> , 2022, 113, 1018-1027.	1.7	4
5	Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study. <i>Esophagus</i> , 2022, 19, 444-451.	1.0	3
6	A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. <i>Journal of Clinical Oncology</i> , 2022, 40, 238-238.	0.8	109
7	Correlation of combined positive score of PD-L1 expression and clinical efficacy for advanced esophageal squamous cell carcinoma treated with nivolumab monotherapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 289-289.	0.8	4
8	Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2022, 386, 449-462.	13.9	419
9	Gastroenterology; Reply to "Letter to the Editor" (<750 w) 739 w. <i>Gastroenterology</i> , 2022, , .	0.6	0
10	Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. <i>JCO Precision Oncology</i> , 2022, 6, e2100383.	1.5	8
11	Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience. <i>BMC Cancer</i> , 2022, 22, 268.	1.1	5
12	Multiple cancer type classification by small RNA expression profiles with plasma samples from multiple facilities. <i>Cancer Science</i> , 2022, 113, 2144-2166.	1.7	7
13	JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma. <i>Cancer Cell</i> , 2022, 40, 238-240.	7.7	12
14	Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3). <i>Clinical Cancer Research</i> , 2022, 28, 3277-3286.	3.2	27
15	Management of elderly patients with esophageal squamous cell cancer. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 816-824.	0.6	4
16	Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3065-3076.	0.8	97
17	Pembrolizumab for the treatment of advanced esophageal cancer. <i>Future Oncology</i> , 2022, 18, 2311-2319.	1.1	2
18	Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies: supplementary analysis of the JCOG trial: JCOG0502. <i>Journal of Gastroenterology</i> , 2022, , .	2.3	4

#	ARTICLE	IF	CITATIONS
19	First-line pembrolizumab+chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590. <i>Esophagus</i> , 2022, 19, 683-692.	1.0	11
20	Phase III study of pembrolizumab combined with S-1+oxaliplatin or S-1+cisplatin as first-line chemotherapy for gastric cancer. <i>Cancer Science</i> , 2022, 113, 2814-2827.	1.7	10
21	Long-term outcomes of patients with recurrent squamous cell carcinoma of the esophagus undergoing salvage endoscopic resection after definitive chemoradiotherapy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 1766-1776.	1.3	9
22	Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3). <i>Esophagus</i> , 2021, 18, 90-99.	1.0	30
23	Determination of novel CYP2D6 haplotype using the targeted sequencing followed by the long-read sequencing and the functional characterization in the Japanese population. <i>Journal of Human Genetics</i> , 2021, 66, 139-149.	1.1	17
24	Nivolumab for the Treatment of Esophageal Squamous Cell Carcinoma. <i>Oncology & Hematology Review</i> , 2021, 16, 90.	0.2	0
25	FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma (JCOG1804E) – The short-term results of cohort A and B. <i>Journal of Clinical Oncology</i> , 2021, 39, 202-202.	0.8	13
26	A novel combination of serum microRNAs for the detection of early gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 835-843.	2.7	18
27	Functional Characterization of the Effects of N-acetyltransferase 2 Alleles on N-acetylation of Eight Drugs and Worldwide Distribution of Substrate-Specific Diversity. <i>Frontiers in Genetics</i> , 2021, 12, 652704.	1.1	9
28	Nivolumab for the treatment of esophageal cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1-7.	1.4	9
29	KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. <i>Future Oncology</i> , 2021, 17, 1143-1153.	1.1	63
30	Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07). <i>Esophagus</i> , 2021, 18, 835-843.	1.0	15
31	Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study. <i>Journal of Clinical Oncology</i> , 2021, 39, LBA4001-LBA4001.	0.8	65
32	Comprehensive serum and tissue microRNA profiling in dedifferentiated liposarcoma. <i>Oncology Letters</i> , 2021, 22, 623.	0.8	11
33	Emerging data on nivolumab for esophageal squamous cell carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 845-854.	1.4	1
34	Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma. <i>Gastroenterology</i> , 2021, 161, 1878-1886.e2.	0.6	51
35	Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. <i>Lancet</i> , 2021, 398, 759-771.	6.3	642
36	Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study. <i>PLoS ONE</i> , 2021, 16, e0257551.	1.1	0

#	ARTICLE	IF	CITATIONS
37	Long-term survival of patients with T1bN0M0 esophageal cancer after thoroscopic esophagectomy using data from JCOG0502: a prospective multicenter trial. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, , 1.	1.3	1
38	Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1899-1903.	15.2	110
39	Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy. <i>Cancer Medicine</i> , 2020, 9, 595-604.	1.3	16
40	Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4138-4148.	0.8	614
41	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. <i>Nature Medicine</i> , 2020, 26, 1859-1864.	15.2	209
42	Immuno-oncology for esophageal cancer. <i>Future Oncology</i> , 2020, 16, 2673-2681.	1.1	16
43	Development of chemotherapeutics for unresectable advanced esophageal cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 1083-1092.	1.1	9
44	Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTIER (JCOG1804E). <i>Future Oncology</i> , 2020, 16, 1351-1357.	1.1	41
45	Comparison of involved field radiotherapy and elective nodal irradiation in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1098-1104.	1.0	11
46	A miRNA-based diagnostic model predicts resectable lung cancer in humans with high accuracy. <i>Communications Biology</i> , 2020, 3, 134.	2.0	72
47	Pembrolizumab for the treatment of esophageal cancer. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1143-1150.	1.4	14
48	Risk Factors of Severe Benign Cicatricial Stricture After Definitive Chemoradiation for Localized T3 Esophageal Carcinoma. <i>Anticancer Research</i> , 2020, 40, 1071-1077.	0.5	2
49	Highly Sensitive Circulating MicroRNA Panel for Accurate Detection of Hepatocellular Carcinoma in Patients With Liver Disease. <i>Hepatology Communications</i> , 2020, 4, 284-297.	2.0	53
50	Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1223-1232.	1.0	22
51	The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909. <i>Esophagus</i> , 2020, 17, 417-424.	1.0	8
52	Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. <i>Cancer Science</i> , 2020, 111, 1676-1684.	1.7	21
53	Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in gastrointestinal cancer patients with massive ascites treated with systemic chemotherapy. <i>Supportive Care in Cancer</i> , 2020, 28, 5861-5869.	1.0	11
54	TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma. <i>BMC Cancer</i> , 2020, 20, 336.	1.1	27

#	ARTICLE	IF	CITATIONS
55	Final analysis of single-arm confirmatory study of definitive chemoradiotherapy including salvage treatment in patients with clinical stage II/III esophageal carcinoma: JCOG0909.. Journal of Clinical Oncology, 2020, 38, 4545-4545.	0.8	7
56	Relationship between cervical esophageal squamous cell carcinoma and human papilloma virus infection and gene mutations. Molecular and Clinical Oncology, 2020, 14, 41.	0.4	2
57	Chemotherapy and Chemoradiotherapy. , 2020, , 253-282.		0
58	Serum level of octanoic acid predicts the efficacy of chemotherapy for colorectal cancer. Oncology Letters, 2019, 17, 831-842.	0.8	10
59	Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma. International Journal of Clinical Oncology, 2019, 24, 60-67.	1.0	12
60	Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE). Japanese Journal of Clinical Oncology, 2019, 49, 1055-1060.	0.6	46
61	Identification of serum microRNAs predicting the response of esophageal squamous-cell carcinoma to nivolumab. Japanese Journal of Clinical Oncology, 2019, 50, 114-121.	0.6	13
62	Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 1506-1517.	5.1	767
63	Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer. PLoS ONE, 2019, 14, e0222024.	1.1	24
64	Gastric mucosal injury and hemorrhage after definitive chemoradiotherapy for locally advanced esophageal cancer. Esophagus, 2019, 16, 402-407.	1.0	5
65	Development and Validation of an Esophageal Squamous Cell Carcinoma Detection Model by Large-Scale MicroRNA Profiling. JAMA Network Open, 2019, 2, e194573.	2.8	56
66	A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes. Nature Communications, 2019, 10, 1299.	5.8	66
67	Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer. Clinical Cancer Research, 2019, 25, 3016-3025.	3.2	87
68	Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy. Japanese Journal of Clinical Oncology, 2019, 49, 412-420.	0.6	110
69	KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncology, 2019, 15, 1057-1066.	1.1	132
70	Serum microRNA profile enables preoperative diagnosis of uterine leiomyosarcoma. Cancer Science, 2019, 110, 3718-3726.	1.7	24
71	Comparison of long-term outcomes between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal squamous cell carcinoma. Journal of Thoracic Disease, 2019, 11, 4654-4662.	0.6	3
72	Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus, 2019, 16, 1-24.	1.0	394

#	ARTICLE	IF	CITATIONS
73	Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus, 2019, 16, 25-43.	1.0	321
74	Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer. Gastric Cancer, 2019, 22, 778-784.	2.7	13
75	Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus. JAMA Oncology, 2019, 5, 546.	3.4	366
76	Serum miRNA-based Prediction of Axillary Lymph Node Metastasis in Breast Cancer. Clinical Cancer Research, 2019, 25, 1817-1827.	3.2	40
77	A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). Gastric Cancer, 2019, 22, 344-354.	2.7	60
78	Circulating miRNA panels for specific and early detection in bladder cancer. Cancer Science, 2019, 110, 408-419.	1.7	175
79	Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.. Journal of Clinical Oncology, 2019, 37, 4010-4010.	0.8	38
80	Evaluation of safety and tolerability of durvalumab (D) and tremelimumab (T) in combination with first-line chemotherapy in patients (pts) with esophageal squamous-cell carcinoma (ESCC).. Journal of Clinical Oncology, 2019, 37, 146-146.	0.8	7
81	Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.. Journal of Clinical Oncology, 2019, 37, 2-2.	0.8	136
82	Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study. Cancer Science, 2018, 109, 785-793.	1.7	16
83	Type of second primary malignancy after achieving complete response by definitive chemoradiation therapy in patients with esophageal squamous cell carcinoma. International Journal of Clinical Oncology, 2018, 23, 652-658.	1.0	11
84	A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma. International Journal of Clinical Oncology, 2018, 23, 466-472.	1.0	39
85	Patterns of Relapse after Definitive Chemoradiotherapy in Stage II/III (Non-T4) Esophageal Squamous Cell Carcinoma. Oncology, 2018, 94, 47-54.	0.9	12
86	Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solid tumors. Cancer Science, 2018, 109, 3253-3262.	1.7	14
87	Integrated extracellular microRNA profiling for ovarian cancer screening. Nature Communications, 2018, 9, 4319.	5.8	213
88	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2018, 392, 123-133.	6.3	984
89	CheckMate 648: A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2018, 36, TPS193-TPS193.	0.8	17
90	Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e132-e137.	0.7	4

#	ARTICLE	IF	CITATIONS
91	Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A). Japanese Journal of Clinical Oncology, 2017, 47, 480-486.	0.6	35
92	Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncology, The, 2017, 18, 631-639.	5.1	324
93	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 2461-2471.	6.3	1,749
94	Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303). International Journal of Clinical Oncology, 2017, 22, 1042-1049.	1.0	32
95	Decreased risk of esophageal cancer owing to cigarette and alcohol cessation in smokers and drinkers: a systematic review and meta-analysis. Esophagus, 2017, 14, 290-302.	1.0	3
96	Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303).. Journal of Clinical Oncology, 2017, 35, 4069-4069.	0.8	8
97	Risk Factors for Esophageal Fistula Associated With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Cancer. Medicine (United States), 2016, 95, e3699.	0.4	60
98	The Prevalence of Overall and Initial Lymph Node Metastases in Clinical T1N0 Thoracic Esophageal Cancer. Annals of Surgery, 2016, 264, 1009-1015.	2.1	85
99	A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Cancer Chemotherapy and Pharmacology, 2016, 78, 91-99.	1.1	49
100	Chemoradiotherapy for esophageal squamous cell cancer. Japanese Journal of Clinical Oncology, 2016, 46, 805-810.	0.6	37
101	Chemoradiation therapy with docetaxel in elderly patients with stage II/III esophageal cancer: A phase 2 trial. Advances in Radiation Oncology, 2016, 1, 230-236.	0.6	11
102	Active salvage chemotherapy versus best supportive care for patients with recurrent or metastatic squamous cell carcinoma of the esophagus refractory or intolerable to fluorouracil, platinum, and taxane. Cancer Chemotherapy and Pharmacology, 2016, 78, 1209-1216.	1.1	8
103	Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. British Journal of Cancer, 2016, 115, 1328-1334.	2.9	108
104	Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors. Investigational New Drugs, 2016, 34, 750-759.	1.2	28
105	Neo-adjuvant therapy or definitive chemoradiotherapy can improve laryngeal preservation rates in patients with cervical esophageal cancer. A Japanese nationwide survey. Esophagus, 2016, 13, 276-282.	1.0	6
106	A nation-wide survey of follow-up strategies for esophageal cancer patients after a curative esophagectomy or a complete response by definitive chemoradiotherapy in Japan. Esophagus, 2016, 13, 173-181.	1.0	18
107	Phase II trial of chemoradiotherapy with concurrent Sâ€1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604). Cancer Science, 2015, 106, 1414-1420.	1.7	28
108	Multicenter questionnaire survey on patterns of care for elderly patients with esophageal squamous cell carcinoma by the Japan Esophageal Oncology Group. Japanese Journal of Clinical Oncology, 2015, 46, 183.	0.6	11

#	ARTICLE	IF	CITATIONS
109	ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 453-463.	1.2	21
110	A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods of Japan Clinical Oncology Group study JCOG1314 (MIRACLE study). <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 494-498.	0.6	24
111	Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907). <i>Oncology</i> , 2015, 89, 143-151.	0.9	29
112	Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). <i>Cancer Science</i> , 2015, 106, 407-412.	1.7	116
113	Chemotherapy and Chemoradiotherapy. , 2015, , 197-225.		1
114	A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1207-1215.	1.1	29
115	Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG 0807). <i>Cancer Science</i> , 2014, 105, 1189-1195.	1.7	61
116	Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912. <i>Gastric Cancer</i> , 2014, 17, 522-528.	2.7	22
117	A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI). <i>Esophagus</i> , 2014, 11, 183-188.	1.0	28
118	The feasibility of a short bevacizumab infusion in patients with metastatic colorectal cancer. <i>Anticancer Research</i> , 2014, 34, 1053-6.	0.5	1
119	A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients. <i>International Journal of Clinical Oncology</i> , 2013, 18, 1020-1024.	1.0	6
120	Phase II Study of Concurrent Chemoradiotherapy at the Dose of 50.4 Gy with Elective Nodal Irradiation for Stage II-III Esophageal Carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 608-615.	0.6	78
121	Three-arm Phase III Trial Comparing Cisplatin Plus 5-FU (CF) Versus Docetaxel, Cisplatin Plus 5-FU (DCF) Versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT Study). <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 752-755.	0.6	257
122	Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2013, 104, 1455-1460.	1.7	181
123	Treatment for Advanced Esophageal Cancer with Metastasis to Distant Organs and/or Lymph Nodes. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 2013, 64, 345-353.	0.0	0
124	A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2012, 30, 2026-2031.	1.2	11
125	Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. <i>Investigational New Drugs</i> , 2012, 30, 1621-1627.	1.2	213
126	Chemoradiotherapy for Elderly Patients with Esophageal Cancer. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 2012, 63, 383-391.	0.0	0

#	ARTICLE	IF	CITATIONS
127	A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1265-1272.	1.1	102
128	Phase II Study of Chemoradiotherapy With 5-Fluorouracil and Cisplatin for Stage II-III Esophageal Squamous Cell Carcinoma: JCOG Trial (JCOG 9906). <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 684-690.	0.4	303
129	Systemic chemotherapy for peritoneal disseminated gastric cancer with inadequate oral intake: a retrospective study. <i>International Journal of Clinical Oncology</i> , 2011, 16, 57-62.	1.0	18
130	Severe late toxicities after definitive chemoradiotherapy. <i>Esophagus</i> , 2011, 8, 315-320.	1.0	1
131	A Multicenter Phase-II Study of 5-FU, Leucovorin and Oxaliplatin (FOLFOX6) in Patients with Pretreated Metastatic Colorectal Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 63-68.	0.6	7
132	Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 913-920.	0.6	40
133	Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1059-1064.	1.2	16
134	A Phase I Trial of 5-Fluorouracil with Cisplatin and Concurrent Standard-dose Radiotherapy in Japanese Patients with Stage II/III Esophageal Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2008, 39, 37-42.	0.6	6
135	Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. <i>Journal of Human Genetics</i> , 2007, 52, 804-819.	1.1	51